Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults
Phase 2
Completed
- Conditions
- Antibiotic-associated Diarrhea
- Registration Number
- NCT01143623
- Lead Sponsor
- Changhai Hospital
- Brief Summary
The purpose of this study is to determine the dose response effect of probiotic capsules for the prevention of antibiotic-associated diarrhea (AAD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 510
Inclusion Criteria
- age 30-70 years
- initiating antibiotic therapy
- informed consent
Exclusion Criteria
- current diarrhea
- life threatening illness
- habitual probiotic use
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Incidence of antibiotic-associated diarrhea 5 weeks after antibiotic discontinuation
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie probiotic efficacy in preventing AAD in NCT01143623?
How does the proprietary probiotic formula in NCT01143623 compare to standard-of-care treatments for AAD prevention?
Are specific gut microbiota biomarkers predictive of response to probiotic intervention in NCT01143623?
What adverse events were observed in NCT01143623 and how were they managed in AAD prevention?
What are the potential synergistic effects of combining the NCT01143623 probiotic with other AAD prophylactic agents?
Trial Locations
- Locations (1)
Changhai Hospital
🇨🇳Shanghai, China
Changhai Hospital🇨🇳Shanghai, China